IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CRIMINI, EDOARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.944
AS - Asia 1.754
NA - Nord America 1.334
SA - Sud America 170
AF - Africa 40
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.257
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.264
DE - Germania 966
CN - Cina 502
SG - Singapore 481
IT - Italia 313
HK - Hong Kong 191
SE - Svezia 150
BD - Bangladesh 146
VN - Vietnam 145
BR - Brasile 126
IN - India 123
FR - Francia 113
RU - Federazione Russa 98
GB - Regno Unito 88
NL - Olanda 54
FI - Finlandia 45
CA - Canada 30
IE - Irlanda 28
JP - Giappone 27
ID - Indonesia 24
TR - Turchia 24
MX - Messico 22
ES - Italia 20
PL - Polonia 16
KR - Corea 15
CI - Costa d'Avorio 13
AT - Austria 12
AU - Australia 11
CO - Colombia 10
EG - Egitto 9
AR - Argentina 8
LB - Libano 8
PK - Pakistan 8
PH - Filippine 7
SA - Arabia Saudita 7
TW - Taiwan 7
UZ - Uzbekistan 7
VE - Venezuela 7
BE - Belgio 6
EC - Ecuador 6
IQ - Iraq 6
JM - Giamaica 6
CH - Svizzera 5
PE - Perù 5
CL - Cile 4
RO - Romania 4
TH - Thailandia 4
UA - Ucraina 4
GR - Grecia 3
HU - Ungheria 3
IR - Iran 3
KZ - Kazakistan 3
MY - Malesia 3
NZ - Nuova Zelanda 3
SD - Sudan 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CR - Costa Rica 2
DZ - Algeria 2
ET - Etiopia 2
HN - Honduras 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
OM - Oman 2
PA - Panama 2
SC - Seychelles 2
SV - El Salvador 2
TN - Tunisia 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EE - Estonia 1
GA - Gabon 1
GI - Gibilterra 1
GT - Guatemala 1
IL - Israele 1
LK - Sri Lanka 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
MT - Malta 1
NO - Norvegia 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
UY - Uruguay 1
Totale 5.257
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 906
Ashburn 264
Singapore 221
Hong Kong 164
San Jose 104
Hefei 86
Dallas 80
Beijing 77
Santa Clara 75
Council Bluffs 66
Milan 66
Los Angeles 55
Chandler 54
New York 52
Hanoi 40
Boardman 39
Bengaluru 38
Helsinki 35
Lauterbourg 34
Ho Chi Minh City 32
Buffalo 29
Moscow 27
Southend 27
Dublin 24
Rome 23
Shanghai 23
Hyderabad 22
Chennai 17
Jakarta 16
Tokyo 16
Guangzhou 15
London 15
Princeton 15
Naples 14
São Paulo 14
Abidjan 13
Boston 12
Florence 12
Istanbul 12
Munich 12
Düsseldorf 11
Nuremberg 10
Seoul 10
Bologna 9
Phoenix 9
Barcelona 8
Cairo 8
Cangzhou 8
Chicago 8
Fuzhou 8
Gdansk 8
Paris 8
Turin 8
Atlanta 7
Cambridge 7
Da Nang 7
Des Moines 7
Lappeenranta 7
Oklahoma City 7
Washington 7
Ann Arbor 6
Bari 6
Brooklyn 6
Madrid 6
Mexico City 6
Orem 6
Palermo 6
Tashkent 6
Toronto 6
Valencia 6
Warsaw 6
Bexley 5
Brussels 5
Charlotte 5
Columbus 5
Houston 5
Lanester 5
Roubaix 5
Seattle 5
Shenzhen 5
Sydney 5
The Dalles 5
Bergamo 4
Berlin 4
Bogotá 4
Brasília 4
Can Tho 4
Cuauhtémoc 4
Denver 4
Dong Ket 4
Hangzhou 4
Manchester 4
Montreal 4
Nanjing 4
New Delhi 4
Piscataway 4
Rio de Janeiro 4
San Francisco 4
Stockholm 4
Taipei 4
Totale 3.201
Salva come PNG Salva come JPEG
Nome #
Margetuximab for the treatment of HER2-positive metastatic breast cancer 537
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 283
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 271
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 244
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population 235
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 202
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 193
Precision medicine in breast cancer : From clinical trials to clinical practice 190
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? 187
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 182
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 175
Adjuvant treatment of early male breast cancer 173
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? 164
Clinical development and current role of margetuximab for the treatment of breast cancer 162
Characterization of low HER2 expressions in de-novo metastatic breast cancer 159
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 157
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 153
COVID-19 related risk in patients enrolled in early-phase clinical trials 146
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 146
Molecular tumor board in patients with metastatic breast cancer 142
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis 126
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 119
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 118
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 114
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis 107
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running? 106
SARS-CoV-2 vaccines for cancer patients: a call to action 106
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology 103
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability 100
Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go? 92
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative 87
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers 84
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial 10
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards 7
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study 7
null 6
Molecular tumour board in gastrointestinal cancers 6
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data 4
Variant allele frequency: a decision-making tool in precision oncology? 4
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 3
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies 1
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting 1
The role of the molecular tumor board: learnings from the ROME trial 1
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions 1
Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer 1
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial 1
Totale 5.416
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202131 0 0 0 0 0 0 0 0 0 0 0 31
2021/2022162 3 8 9 10 9 9 1 22 29 19 23 20
2022/2023320 26 33 42 21 42 42 5 13 39 16 28 13
2023/20241.000 29 30 22 48 94 59 150 117 64 104 144 139
2024/20251.294 116 147 116 121 87 49 19 126 78 116 125 194
2025/20262.586 324 260 266 210 155 86 325 88 230 162 305 175
Totale 5.416